secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2024-09-17T23:59:59+00:00
Accession:  0001654954-24-012031
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata raises $3.5M gross in private placement; expects cash runway into Q2 2025
--------------------------------------------------------------------------------

- Gross proceeds $3.5M from 1,912,569 shares/pre-funded warrants + Series A & B warrants at $1.83/unit.
- Net proceeds ~$3.0M after placement agent fees; H.C. Wainwright acted as exclusive agent.
- Series A warrants (5.5 yr term) and Series B warrants (18 mo term) each exercisable at $1.58/share.
- Including prior raises, total $7.8M gross since May 2024; operations funded into Q2 2025.
- Proceeds for general corporate purposes including R&D, clinical trials, and licensing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000165495424012031/0001654954-24-012031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000165495424012031/drma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-012031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer